Provided by Tiger Fintech (Singapore) Pte. Ltd.

Inhibikase Therapeutics, Inc.

2.20
-0.0550-2.44%
Volume:16.26K
Turnover:35.95K
Market Cap:163.18M
PE:-1.89
High:2.30
Open:2.18
Low:2.11
Close:2.25
Loading ...

Insiders Enjoy US$1.1m Return After Buying Inhibikase Therapeutics Stock

Simply Wall St.
·
31 Jan

Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study

Reuters
·
30 Jan

BRIEF-Inhibikase Therapeutics Inc Says 201 Trial Met Primary Endpoint Of Safety And Tolerability

Reuters
·
30 Jan

Inhibikase Therapeutics Inc - Risvodetinib Treatment Did Not Show Improvement in Top Hierarchical Efficacy Measure

THOMSON REUTERS
·
30 Jan

Inhibikase Therapeutics Inc - 201 Trial Met Primary Endpoint of Safety and Tolerability

THOMSON REUTERS
·
30 Jan

Bullish Inhibikase Therapeutics Insiders Loaded Up On US$2.70m Of Stock

Simply Wall St.
·
21 Jan

Inhibikase Adjusts and Terminates Stock Offering Agreement

TIPRANKS
·
06 Dec 2024

Inhibikase Therapeutics Inc - Terminates Atm Agreement With With H.c. Wainwright & Co Llc Effective December 11, 2024

THOMSON REUTERS
·
06 Dec 2024

Inhibikase Therapeutics files to sell 58.31M shares of common stock for holders

TIPRANKS
·
19 Nov 2024

Inhibikase Therapeutics: Strategic Developments and Financial Position Underpin Buy Rating

TIPRANKS
·
16 Nov 2024

Inhibikase Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
15 Nov 2024

Inhibikase Therapeutics Q3 Net Income USD -5.8 Million

THOMSON REUTERS
·
14 Nov 2024

Inhibikase Therapeutics Q3 EPS USD -0.65

THOMSON REUTERS
·
14 Nov 2024

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

THOMSON REUTERS
·
14 Nov 2024

Press Release: Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

Dow Jones
·
14 Nov 2024

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
11 Nov 2024

Inhibikase Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview

Reuters
·
09 Nov 2024

Jefferies Initiates Inhibikase Therapeutics With Buy Rating, $8 Price Target

MT Newswires Live
·
08 Nov 2024